XORTX Therapeutics Inc. (XRTX)
NASDAQ: XRTX · Real-Time Price · USD
0.435
+0.031 (7.78%)
At close: Mar 5, 2026, 4:00 PM EST
0.435
0.00 (0.00%)
Pre-market: Mar 6, 2026, 8:00 AM EST
XORTX Therapeutics Employees
As of December 31, 2023, XORTX Therapeutics had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$885,435
Market Cap
3.05M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3 | 0 | - |
| Dec 31, 2022 | 3 | 0 | - |
| Jan 1, 2022 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 49 |
| Scinai Immunotherapeutics | 31 |
| Lyra Therapeutics | 30 |
| Dermata Therapeutics | 8 |
| Enveric Biosciences | 6 |
| Artelo Biosciences | 5 |
| Adial Pharmaceuticals | 5 |
| 60 Degrees Pharmaceuticals | 3 |
XRTX News
- 4 weeks ago - Why Align Technology Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Benzinga
- 4 weeks ago - XORTX Extends Closing Of Renal Anti-Fibrotic Therapeutic Program Acquisition; Stock Soars - Nasdaq
- 4 months ago - XORTX Announces Pricing of US$1.1 Million Registered Direct Offering - GlobeNewsWire
- 4 months ago - XORTX Therapeutics (XRTX) Secures Nasdaq Extension to Meet Bid Price Rule - GuruFocus
- 4 months ago - XORTX Therapeutics gains 180-day extension from Nasdaq to regain $1.00 bid price compliance - Seeking Alpha
- 4 months ago - XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency - GlobeNewsWire
- 4 months ago - XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - GlobeNewsWire
- 5 months ago - XORTX (XRTX) Acquires Renal Therapeutic Program from Vectus - GuruFocus